TOWA (6315) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue and earnings declined as profitability deteriorated in the core semiconductor manufacturing equipment business, resulting in a significant retreat in profitability. Revenue was ¥369.3B (-5.9% YoY), Operating Income was ¥36.9B (-43.5%), Ordinary Income was ¥37.0B (-47.8%), and Net Income attributable to owners of the parent was ¥26.3B (-49.0%). The Operating Income margin declined to 10.0%, down 6.6pt from 16.6% in the same period of the previous year, and the decline in profit substantially exceeded the decrease in revenue.

Factors Affecting Performance

【Revenue】Revenue was ¥369.3B, down 5.9% YoY. The core Semiconductor Equipment Business posted revenue of ¥339.4B (91.9% of total, -6.0% YoY), declining and becoming the primary factor behind the consolidated revenue decrease. The Medical Device Business increased revenue to ¥18.7B (5.1% of total, +7.8% YoY), but its small scale was insufficient to offset the decline. The laser processing equipment business also remained sluggish, with revenue down 20.0% YoY, resulting in declines in two of the three businesses.

【Profit and Loss】Operating Income was ¥36.9B, down 43.5% YoY, while the Operating Income margin declined 6.6pt to 10.0% (16.6% in the previous year). The primary factor was the decline in the Semiconductor Equipment Business segment profit margin from 17.2% to 10.1%, which explains nearly all of the deterioration in the consolidated profit margin. The laser processing equipment business posted a widening operating loss, as insufficient fixed-cost absorption continued. Ordinary Income was ¥37.0B (-47.8% YoY), with a foreign exchange loss of ¥3.4B weighing on non-operating income and expenses. Net Income was ¥26.3B (-49.0%). Extraordinary income and expenses were a small net gain of ¥0.8B, indicating that developments through the Ordinary Income stage were the primary cause of the decline in Net Income. In conclusion, this was a decline in revenue and earnings in which reduced fixed-cost absorption associated with lower revenue pushed down profit margins.

Segment Analysis

The semiconductor manufacturing equipment business generated revenue of ¥339.4B (91.9% of total, -6.0% YoY), segment profit of ¥34.3B (-44.8% YoY), and a profit margin of 10.1% (down from 17.2% in the previous year), and it continues to determine nearly the entirety of consolidated performance. The Medical Device Business generated revenue of ¥18.7B (5.1% of total, +7.8% YoY), segment profit of ¥3.5B (-6.1% YoY), and a relatively high profit margin of 18.6%, but its scale is small. The laser processing equipment business generated revenue of ¥11.2B (-20.0% YoY) and posted a widening operating loss of ¥0.9B, with fixed-cost burdens continuing to weigh on consolidated profit.

Key Financial Indicators

【Profitability】The Operating Income margin of 10.0% declined 6.6pt from 16.6% in the same period of the previous year, while the Net Income margin remained at 7.1%. Under the DuPont decomposition, ROE is composed of a 7.1% Net Income margin, total asset turnover of 0.364x, and financial leverage of 1.50x.【Cash Quality】DSO was approximately 95 days and DIO approximately 208 days, resulting in a prolonged CCC of approximately 253 days. The accumulation of work-in-process inventory of ¥117.9B (62.4% of total) is weighing on working-capital efficiency.【Investment Efficiency】ROE was 3.9%, below the general benchmark for capital efficiency of 8%, primarily due to the low total asset turnover ratio.【Financial Soundness】The Equity Ratio declined to 66.6% from 73.8% in the previous year but remained at a high level. With a current ratio of 244.6%, cash and deposits of ¥299.4B, and interest-bearing debt of ¥155.3B, the company maintains a conservative financial structure, with a Debt/Capital ratio of 18.7%.

Cash Flow Analysis

As figures for Operating, Investing, and Financing Cash Flows have not been disclosed, cash trends are analyzed based on movements in the balance sheet. Cash and deposits increased to ¥299.4B from ¥213.4B in the same period of the previous year, while working-capital items also expanded, including accounts receivable of ¥128.2B and work-in-process inventory of ¥117.9B. The prolonged working-capital cycle, comprising DSO of approximately 95 days, DIO of approximately 208 days, and CCC of approximately 253 days, indicates a structure in which it is likely to take longer to convert earnings into cash. The ratio of current liabilities, including short-term borrowings of ¥110.0B, was somewhat high at 70.8%; however, cash and deposits exceeded current liabilities, limiting concerns about near-term liquidity.

Earnings Quality

The difference between Ordinary Income of ¥37.0B and Net Income of ¥26.3B was attributable to income taxes and other taxes of ¥11.5B. Extraordinary income and expenses were a small net gain of ¥0.8B, and Net Income was therefore primarily based on ordinary business and non-operating income and expenses. Non-operating income and expenses comprised income of ¥5.0B, including dividends received of ¥1.1B, against expenses of ¥4.9B, including a foreign exchange loss of ¥3.4B, resulting in an almost complete offset. The foreign exchange loss of ¥3.4B was equivalent to 9.2% of Operating Income and was one factor depressing Ordinary Income. Comprehensive Income was ¥75.9B, substantially exceeding Net Income of ¥26.3B, primarily due to foreign currency translation adjustments of ¥34.9B and valuation differences on securities of ¥15.1B. It should be noted that this does not indicate an improvement in the business’s earning power.

Earnings Forecast and Guidance

The full-year company forecast is revenue of ¥545.0B (+1.9% YoY), Operating Income of ¥70.0B (-21.2%), and Ordinary Income of ¥70.0B (-25.5%). The Q3 cumulative progress rates were 67.8% for revenue, 52.6% for Operating Income, and 52.9% for Ordinary Income, below the normally assumed level of 75%. The delay in Operating Income progress is particularly notable, and the company would need to generate revenue of approximately ¥175.7B in Q4, together with an Operating Income margin substantially exceeding the cumulative 10.0%. Achievement of the full-year plan presupposes concentrated shipments and improved profitability in the core semiconductor manufacturing equipment business.

Shareholder Returns

The Q2 dividend was ¥0 per share, while the full-year company forecast is an annual dividend of ¥20.0 per share. The Payout Ratio against forecast EPS of ¥65.98 is approximately 30.3%, below the general sustainability benchmark of 60%. The financial base of cash and deposits of ¥299.4B and an Equity Ratio of 66.6% supports the capacity to pay dividends. Treasury shares amounted to 129,000 shares, with a book value of ¥1.1B. As no disclosure regarding share buybacks during the current period was identified, the company is evaluated based solely on the Payout Ratio from dividends.

Risk Factors

1. Concentration risk in the semiconductor manufacturing equipment business: This business accounts for 91.9% of consolidated revenue and 93.0% of segment profit, while the decline in its segment profit margin from 17.2% to 10.1% explains nearly all of the deterioration in consolidated profitability. The company has a structure in which supply-and-demand trends in this business directly determine performance.

2. Risk of a prolonged working-capital cycle: The cash collection cycle has lengthened, with DSO of approximately 95 days, DIO of approximately 208 days, and CCC of approximately 253 days. The accumulation of work-in-process inventory of ¥117.9B (62.4% of total) is notable. Delays in customer acceptance and inventory valuation trends could affect future earnings and capital efficiency.

3. Risk of deteriorating profitability in the laser processing equipment business: Revenue in this business declined 20.0% YoY, and its operating loss widened. If demand recovery or fixed-cost reviews are delayed, downward pressure on consolidated profit may continue.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

Profitability exceeds the industry median, although attention should be paid to the sharp decline from the previous year.

Growth and Capital Efficiency

The revenue growth rate is substantially below the industry median, and the extent of the revenue decline is notable even within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Although the Operating Income margin of 10.0% exceeds the industry median, it declined sharply by 6.6pt YoY, making the likelihood of a recovery in profitability a key point of focus.

2. The progress rate against the full-year Operating Income forecast was only 52.6%, indicating that the plan incorporates a significant improvement in profitability in Q4. This will be an important factor in assessing achievement of the full-year plan.

3. The prolonged working-capital cycle, reflected in work-in-process inventory of ¥117.9B and DIO of approximately 208 days, warrants continued monitoring of production and customer-acceptance progress and the timing of cash conversion.

Theoretical Share Price (Reference Value)

Sensitivity: ¥812–¥859 at a ±1% change in the cost of equity, and ¥833–¥836 at a ±0.1 change in ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

TOWA’s FY2026 Q3 cumulative earnings were materially weaker year on year, with modest revenue contraction translating into a sharp profit decline. Revenue was ¥36.93bn, down 5.9% YoY. Operating income fell 43.5% to ¥3.69bn. Ordinary income declined 47.8% to ¥3.70bn, while net income attributable to owners declined 49.0% to ¥2.63bn. The operating margin compressed to 10.0% from 16.6% a year earlier, a 660bp decline. Gross margin fell to 32.7% from 37.1%, a 440bp compression, indicating that lower sales volume and/or product mix had a substantial impact on manufacturing profitability. SG&A expenses rose 4.0% YoY to ¥8.37bn despite the sales decline, increasing the SG&A-to-sales ratio to 22.7% from 20.5%. This negative operating leverage was the principal reason that operating income declined much faster than revenue. The semiconductor manufacturing equipment segment remained the core business, accounting for 91.9% of group revenue and 92.9% of segment profit, but its segment profit fell 44.8% YoY. The medical device segment delivered revenue growth and retained a high segment margin, partly offsetting weakness in the core semiconductor equipment business. The laser processing equipment segment remained loss-making, and its loss widened as revenue declined. Non-operating income was supported by ¥0.13bn of interest income and ¥0.11bn of dividend income, but this was outweighed by ¥0.34bn of foreign-exchange losses within non-operating expenses. Profit before tax exceeded ordinary income because of a net extraordinary gain of ¥0.08bn, which was immaterial relative to net income. Total comprehensive income more than doubled to ¥7.59bn, primarily reflecting positive foreign currency translation and securities valuation movements rather than an improvement in operating earnings. The balance sheet remains liquid and conservatively capitalized, with a 244.6% current ratio, 0.50x debt-to-equity ratio, and cash equal to 2.72x short-term debt. However, the working-capital cycle is extended, with annualized DSO of 95 days, annualized DIO of 208 days, and an annualized cash conversion cycle of 253 days; the high WIP mix indicates elevated execution and inventory-conversion risk. Full-year guidance implies a meaningful Q4 earnings recovery, as Q3 cumulative operating-income progress is only 52.6% against the full-year plan versus a standard 75% progress rate. The central issues for the remainder of FY2026 are recovery in semiconductor equipment margins, conversion of WIP into shipments and cash, and delivery of the guidance-implied Q4 profit acceleration.

Profitability Analysis

The reported annualized ROE is 5.2%, below the 8% level generally associated with adequate equity efficiency. The DuPont decomposition is net profit margin of 7.1% multiplied by annualized asset turnover of 0.486x and financial leverage of 1.50x. The relatively modest leverage is a balance-sheet strength, but it also means that ROE recovery must principally come from improved operating profitability and asset utilization rather than additional leverage. The largest adverse change was profitability: the operating margin fell 660bp YoY to 10.0%, while the net margin declined to 7.1% from approximately 13.1% in the prior-year period. Gross-margin compression of 440bp was compounded by SG&A growth of 4.0% against a 5.9% revenue decline, demonstrating unfavorable operating leverage. Cost of sales rose 0.7% to ¥24.87bn despite lower revenue, which is consistent with a less favorable production-volume absorption and/or mix. The tax burden was 0.695, broadly normal, and the interest burden was 1.025 because profit before tax slightly exceeded EBIT due to the small net extraordinary gain; neither factor explains the earnings decline. Interest coverage remains very strong at 34.32x, so financing costs are not currently constraining profitability. By segment, semiconductor manufacturing equipment generated ¥33.94bn of revenue, down 6.0% YoY, and ¥3.43bn of segment profit, down 44.8%; its segment margin fell to 10.1% from 17.2%. Medical devices generated ¥1.87bn of revenue, up 7.8%, and ¥0.35bn of profit, down 6.1%, with an 18.6% segment margin versus 21.4% a year earlier. Laser processing equipment revenue declined 20.0% to ¥1.12bn and the segment loss widened to ¥0.87bn from ¥0.50bn, equivalent to a negative 7.7% margin. The semiconductor equipment business is therefore the core business and the dominant determinant of consolidated margin direction. The margin contraction appears operational rather than tax- or interest-driven, making normalization dependent on demand, production utilization, pricing, and execution rather than financial engineering.

Growth Assessment

Revenue contracted 5.9% YoY in FY2026 Q3 cumulative results, ending the period below the prior-year high base. The revenue decline was concentrated in semiconductor manufacturing equipment, where sales fell ¥2.18bn YoY. Medical devices added ¥0.13bn of revenue and provided some diversification, but its scale remains insufficient to offset the semiconductor equipment decline. Laser processing equipment reduced group revenue by ¥0.28bn and remained structurally unprofitable during the period. Full-year company guidance calls for revenue of ¥54.50bn, up 1.9% YoY. Q3 cumulative revenue represents 67.8% of guidance, 7.2 percentage points below the standard 75% progress rate for the third quarter, but not more than 10 percentage points below it. In contrast, operating income progress is 52.6% of the ¥7.00bn full-year target, 22.4 percentage points below the standard Q3 pace. Net-income progress is 53.1% of the ¥4.95bn forecast, 21.9 percentage points below standard progress. Achieving guidance therefore requires approximately ¥17.57bn of Q4 revenue and ¥3.32bn of operating income, implying an approximately 18.9% Q4 operating margin. This is substantially above the 10.0% cumulative margin and indicates that management’s plan relies on a sharp improvement in shipment mix, utilization, or cost absorption. The forecast’s full-year operating-income decline of 21.2% YoY nevertheless implies a much less severe decline than the 43.5% reduction recorded through Q3. Profit quality is principally recurring at the operating level; the ¥0.08bn net extraordinary gain was only about 3% of Q3 cumulative net income. Foreign-exchange losses of ¥0.34bn, equivalent to 9.2% of operating income, added volatility below operating profit. Revenue sustainability remains linked predominantly to semiconductor capital-investment cycles, while the smaller medical device business provides a higher-margin but currently limited counterbalance.

Financial Health

Liquidity is strong, with current assets of ¥64.26bn against current liabilities of ¥26.27bn, producing a 244.6% current ratio. The 225.1% quick ratio confirms that liquidity is not dependent on inventory liquidation. Working capital was ¥37.99bn, and cash and deposits totaled ¥29.94bn, equal to 29.5% of total assets. Interest-bearing debt was ¥15.53bn, comprising ¥11.00bn of short-term loans and ¥4.53bn of long-term loans. Debt-to-equity was a conservative 0.50x and debt-to-capital was 18.7%, both well within investment-grade-style benchmarks. Interest coverage of 34.32x provides substantial headroom for the current interest burden. The principal funding risk is refinancing concentration rather than absolute indebtedness: 70.8% of debt is short-term, above the 40% alert threshold. Short-term debt increased ¥4.00bn, or 57.1% YoY, while long-term loans increased ¥3.16bn, or 230.7% YoY. This debt expansion was more than matched by the ¥8.60bn increase in cash and deposits, and cash covered short-term debt by 2.72x, mitigating near-term maturity-mismatch risk. Accounts payable increased ¥2.00bn, or 78.5% YoY, which supplied additional operating funding but should be monitored alongside the extended inventory cycle. Equity increased to ¥67.51bn from ¥61.39bn, supported materially by accumulated other comprehensive income, including foreign-currency translation adjustments. The equity ratio declined to 66.6% from 73.8% as liabilities grew faster than equity, but it remains robust. PPE represented 25.5% of assets and intangible assets only 1.7%, indicating that the balance sheet is not materially dependent on acquired intangibles. No material goodwill movement or segment-level impairment was reported. Defined-benefit liabilities of ¥1.06bn and product-warranty provisions of ¥0.32bn are modest relative to the balance sheet and do not currently indicate a material off-balance-sheet-like funding burden.

Notable B/S Changes

Long-term loans: +¥3.16bn (+230.7%) to ¥4.53bn - longer-term borrowing increased materially, though the absolute balance remains manageable relative to equity and cash. Short-term loans: +¥4.00bn (+57.1%) to ¥11.00bn - short-term financing increased and contributes to the 70.8% short-term debt ratio, requiring refinancing discipline. Cash and deposits: +¥8.60bn (+40.3%) to ¥29.94bn - substantial liquidity growth supports debt servicing and working-capital needs; cash remains 2.72x short-term debt. Accounts payable: +¥2.00bn (+78.5%) to ¥4.55bn - increased supplier financing partly supports working capital, but should be evaluated alongside inventory and receivable conversion. Finished goods: +¥1.29bn (+33.8%) to ¥5.12bn - higher completed inventory adds carrying and demand-conversion risk. Work in process: +¥1.56bn (+15.3%) to ¥11.79bn - although below the 20% change screen, the absolute balance is material and represents 62.4% of manufacturing inventory, indicating elevated production-cycle exposure. Accumulated other comprehensive income: +¥4.96bn to ¥11.55bn - primarily foreign-currency translation and securities valuation gains lifted equity, but this is market-related rather than recurring operating profit.

Cash Flow Quality

The operating cash-flow, investing cash-flow, financing cash-flow, capital-expenditure, and free-cash-flow figures required to assess cash conversion and dividend coverage are not available in the provided financial data. Balance-sheet working-capital indicators nevertheless point to elevated cash-conversion risk. Annualized receivable days of 95 exceed the 60-day warning threshold, indicating slower customer collection or a shipment and billing profile that requires close monitoring. Annualized inventory days of 208 are substantially above the 90-day warning threshold. The annualized cash conversion cycle of 253 days exceeds the 120-day warning threshold, tying up a material amount of capital in operations. Manufacturing inventory composition is particularly important: WIP was ¥11.79bn, compared with raw materials of ¥1.97bn and finished goods of ¥5.12bn. WIP represented 62.4% of manufacturing inventory, well above the 40% warning threshold and consistent with a potential production bottleneck, long lead-time order profile, or delayed conversion into completed shipments. The high-WIP alert is material because the core semiconductor equipment business is project- and production-cycle sensitive. Accounts receivable increased 12.6% YoY to ¥12.82bn, while accounts payable increased 78.5% to ¥4.55bn; the payable increase partly offsets funding needs but does not eliminate the risk associated with the much longer cash conversion cycle. Cash increased 40.3% YoY to ¥29.94bn, providing a substantial liquidity buffer. However, without operating cash flow, the extent to which this cash increase reflects internally generated cash, borrowing, or timing effects cannot be determined. Consequently, conversion of WIP and receivables into operating cash should be a primary monitoring item.

Dividend Sustainability

The full-year dividend forecast is ¥20.00 per share, while the Q2 dividend was ¥0 per share, indicating that the planned shareholder distribution is concentrated in the year-end dividend. Based on forecast EPS of ¥65.98, the forecast dividend payout ratio is approximately 30.3%. This is below the 60% sustainability benchmark and leaves a meaningful earnings retention buffer. The forecast dividend requires approximately ¥1.50bn of aggregate distributions based on 75.0 million average shares, versus forecast net income of ¥4.95bn. The balance sheet provides support, with ¥29.94bn of cash and deposits and ¥46.60bn of retained earnings. Dividend sustainability is therefore sound on an accounting-profit and liquidity basis. The principal qualification is that free-cash-flow coverage cannot be assessed from the available data. Given the 253-day annualized cash conversion cycle and high WIP intensity, sustainable cash coverage depends on timely collection and conversion of production inventory into sales. The planned ¥20 DPS also depends on achieving the full-year earnings forecast, which requires a strong Q4 recovery in operating profit. No share buyback information is provided; accordingly, the analysis is limited to the dividend payout ratio rather than a total return ratio.

Risk Assessment

Business risks include Semiconductor capital-equipment cyclicality is the highest business risk because the semiconductor manufacturing equipment segment accounts for 91.9% of revenue and 92.9% of segment profit. A 6.0% segment revenue decline resulted in a 44.8% segment-profit decline, demonstrating high operating leverage., Production and execution risk is elevated by ¥11.79bn of WIP, representing 62.4% of manufacturing inventory. The high-WIP ratio may reflect long production cycles or bottlenecks and could delay shipment recognition, cash collection, and margin realization., Laser processing equipment remains loss-making, with a ¥0.87bn segment loss on ¥1.12bn of revenue. Continued losses could dilute consolidated margins and require management to improve utilization, cost structure, or product competitiveness., Foreign-exchange risk is material below the operating line: ¥0.34bn of FX losses represented 9.2% of operating income. Exchange-rate movements can therefore affect ordinary income even when operating performance is stable., The guidance-implied Q4 operating margin of approximately 18.9% creates execution risk, as it is substantially above the 10.0% FY2026 Q3 cumulative margin..

Financial risks include Refinancing risk is elevated by a 70.8% short-term debt ratio. Although liquidity is ample and cash covers short-term debt by 2.72x, the debt structure requires continued access to bank funding or internal cash., Receivables collection risk is elevated by annualized DSO of 95 days, above the 60-day alert threshold. Extended customer payment cycles can pressure cash generation and raise credit-risk sensitivity if semiconductor customers weaken., Inventory carrying and obsolescence risk is elevated by annualized DIO of 208 days. Semiconductor equipment inventories and WIP can be exposed to specification changes, order deferrals, and prolonged project lead times., The annualized cash conversion cycle of 253 days is substantially above the 120-day warning level. This increases the amount of funding required to support growth and heightens sensitivity to demand disruption., The equity ratio declined from 73.8% to 66.6% as debt and other liabilities increased faster than equity. Capitalization remains strong, but the direction of change should be monitored if borrowing continues to rise..

Key concerns include Margin compression is severe: the operating margin fell 660bp YoY to 10.0%, driven by a 440bp gross-margin decline and a 220bp rise in the SG&A-to-sales ratio., Profit recovery is back-end loaded. Operating-income progress of 52.6% versus the full-year forecast is 22.4 percentage points below the standard Q3 progress rate., The combination of high WIP, high inventory days, high receivable days, and a long cash conversion cycle is the key operational-financial linkage to monitor., Comprehensive income was boosted by ¥4.96bn of OCI, including foreign-currency translation and securities valuation effects. This strengthens reported equity but should not be interpreted as operating earnings recovery..

Investment Implications

Key takeaways include The earnings shortfall is primarily a margin and operating-leverage issue rather than a balance-sheet stress event., Semiconductor manufacturing equipment remains the core earnings engine; its margin recovery will determine whether group guidance is achievable., Medical devices offer a smaller but profitable diversification source, while laser processing equipment remains a drag on consolidated earnings., High liquidity and moderate leverage provide resilience, but the short-term funding mix and lengthy working-capital cycle require attention., The ¥20 full-year DPS forecast implies a moderate 30.3% payout ratio based on forecast EPS, subject to Q4 earnings and cash conversion..

Metrics to watch include Semiconductor manufacturing equipment segment revenue and segment margin, Q4 operating margin versus the approximately 18.9% margin implied by full-year guidance, Annualized DSO, DIO, and cash conversion cycle, WIP balance and WIP share of total manufacturing inventory, Short-term debt ratio, cash-to-short-term-debt coverage, and debt growth, Foreign-exchange gains or losses relative to operating income, Operating cash flow and free cash flow when reported.

Regarding relative positioning, TOWA combines a strong liquidity position, conservative 0.50x debt-to-equity ratio, and high 34.32x interest coverage with weaker-than-desired annualized ROE of 5.2% and a materially extended working-capital cycle. Its 10.0% operating margin remains within a generally acceptable manufacturing range, but the abrupt 660bp YoY compression and high dependence on semiconductor equipment make earnings more cyclical and execution-sensitive than the balance sheet alone suggests.